NYSE:MCK - McKesson Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $214.00
  • Forecasted Upside: 13.40 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$188.72
▲ +3.83 (2.07%)

This chart shows the closing price for MCK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New McKesson Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MCK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MCK

Analyst Price Target is $214.00
▲ +13.40% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for McKesson in the last 3 months. The average price target is $214.00, with a high forecast of $257.00 and a low forecast of $166.00. The average price target represents a 13.40% upside from the last price of $188.72.

This chart shows the closing price for MCK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in McKesson. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2021MizuhoBoost Price TargetNeutral$190.00 ➝ $205.00Low
5/10/2021Credit Suisse GroupBoost Price TargetNeutral$192.00 ➝ $222.00Medium
5/7/2021The Goldman Sachs GroupBoost Price TargetBuy$231.00 ➝ $257.00High
5/7/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$231.00 ➝ $237.00High
3/30/2021ArgusUpgradeHold ➝ Buy$230.00Low
3/2/2021CowenBoost Price TargetPositive ➝ Outperform$210.00 ➝ $224.00Low
2/3/2021Morgan StanleyBoost Price TargetOverweight$219.00 ➝ $226.00Low
2/3/2021Credit Suisse GroupBoost Price TargetNeutral$178.00 ➝ $192.00Low
2/3/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$222.00 ➝ $231.00Low
2/3/2021MizuhoBoost Price TargetNeutral$178.00 ➝ $190.00Low
2/1/2021CowenBoost Price TargetOutperform$186.00 ➝ $210.00Low
11/18/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyLow
11/13/2020MizuhoBoost Price TargetNeutral$150.00 ➝ $178.00Medium
11/5/2020Credit Suisse GroupBoost Price TargetNeutral$174.00 ➝ $178.00Medium
11/4/2020Morgan StanleyBoost Price TargetOverweight$204.00 ➝ $219.00High
11/4/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$202.00 ➝ $222.00High
11/2/2020BarclaysUpgradeEqual Weight ➝ Overweight$166.00 ➝ $166.00Medium
8/4/2020JPMorgan Chase & Co.Boost Price TargetPositive ➝ Overweight$187.00 ➝ $198.00Low
8/4/2020Credit Suisse GroupBoost Price TargetNeutral$160.00 ➝ $162.00Low
8/4/2020Morgan StanleyBoost Price TargetOverweight$194.00 ➝ $204.00Medium
8/4/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$169.00 ➝ $202.00Medium
7/8/2020GuggenheimBoost Price TargetBuy$168.00 ➝ $175.00Medium
6/15/2020Morgan StanleyBoost Price TargetOverweight$163.00 ➝ $194.00Medium
5/27/2020GuggenheimBoost Price TargetBuy$147.00 ➝ $168.00High
5/26/2020UBS GroupBoost Price TargetBuy$160.00 ➝ $165.00Low
5/22/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$184.00Low
5/22/2020Morgan StanleyBoost Price TargetOverweight$150.00 ➝ $163.00Low
5/21/2020CowenBoost Price TargetOutperform$174.00 ➝ $186.00Low
5/21/2020Deutsche Bank AktiengesellschaftLower Price TargetHold$173.00 ➝ $169.00Low
5/21/2020MizuhoBoost Price TargetNeutral$140.00 ➝ $147.00Low
5/20/2020CfraLower Price TargetBuy$179.00 ➝ $171.00Medium
5/15/2020UBS GroupUpgradeNeutral ➝ Buy$151.00 ➝ $160.00High
4/22/2020Credit Suisse GroupInitiated CoverageNeutral$146.00Low
4/2/2020Credit Suisse GroupLower Price TargetNeutral$155.00 ➝ $147.00High
3/31/2020BarclaysLower Price TargetEqual Weight$170.00 ➝ $163.00Medium
3/27/2020Morgan StanleyLower Price TargetOverweight$182.00 ➝ $150.00Low
3/18/2020Credit Suisse GroupReiterated RatingHold$145.00Medium
3/18/2020JPMorgan Chase & Co.Boost Price TargetOverweight$186.00 ➝ $187.00High
3/18/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$173.00 ➝ $174.00High
3/13/2020GuggenheimUpgradeNeutral ➝ BuyMedium
3/6/2020Morgan StanleyReiterated RatingBuy$182.00Medium
2/11/2020Morgan StanleyBoost Price TargetOverweight$168.00 ➝ $182.00Medium
2/7/2020Robert W. BairdUpgradeNeutral ➝ Outperform$164.00 ➝ $197.00Medium
2/5/2020Robert W. BairdBoost Price TargetNeutral$161.00 ➝ $164.00Medium
2/5/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$153.00 ➝ $173.00Medium
2/5/2020Morgan StanleyBoost Price TargetOverweight$162.00 ➝ $168.00Medium
1/19/2020BarclaysReiterated RatingHold$170.00Low
1/15/2020MizuhoBoost Price TargetNeutral$137.00 ➝ $140.00High
1/10/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$135.00 ➝ $162.00Medium
1/9/2020UBS GroupDowngradeSell$147.00High
9/12/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$155.00Medium
9/5/2019Cleveland ResearchReiterated RatingHoldLow
8/27/2019Morgan StanleyBoost Price TargetEqual Weight$130.00 ➝ $135.00High
8/5/2019Wolfe ResearchDowngradeOutperform ➝ Peer PerformLow
7/31/2019Bank of AmericaSet Price TargetBuy$160.00N/A
7/22/2019Credit Suisse GroupInitiated CoverageNeutral$143.00Low
7/22/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$152.00Low
7/22/2019JPMorgan Chase & Co.Initiated CoverageOverweight$164.00Low
4/2/2019Wolfe ResearchInitiated CoverageOutperformHigh
2/1/2019BarclaysReiterated RatingHold$130.00Medium
1/25/2019Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$175.00Low
1/17/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$134.00Low
1/6/2019BarclaysReiterated RatingHold$124.00Low
12/9/2018Morgan StanleyLower Price Target$142.00 ➝ $130.00Low
12/3/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$142.00 ➝ $130.00Medium
10/26/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$150.00 ➝ $136.00High
10/26/2018Royal Bank of CanadaSet Price TargetHold$155.00Medium
8/12/2018MizuhoReiterated RatingHold$133.00High
7/27/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$181.00 ➝ $160.00Low
7/27/2018Jefferies Financial GroupReiterated RatingBuy$160.00Medium
7/27/2018Royal Bank of CanadaReiterated RatingHold$152.00Medium
7/20/2018Robert W. BairdDowngradeOutperform ➝ NeutralLow
7/20/2018CitigroupLower Price TargetBuy$160.00 ➝ $2.86Low
7/10/2018Standpoint ResearchUpgradeHold ➝ BuyLow
7/3/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$175.00 ➝ $142.00Low
6/29/2018Royal Bank of CanadaLower Price TargetMarket Perform$158.00High
5/29/2018SVB LeerinkSet Price TargetMarket Perform ➝ Market Perform$170.00 ➝ $160.00High
4/11/2018Bank of AmericaLower Price TargetBuy ➝ Buy$179.00 ➝ $172.00Low
3/8/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$165.00Medium
2/27/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$179.00Low
2/2/2018Credit Suisse GroupReiterated RatingSell$130.00High
2/2/2018MizuhoLower Price TargetNeutral ➝ Neutral$186.00 ➝ $179.00High
1/24/2018MizuhoSet Price TargetHold$186.00Low
1/24/2018Jefferies Financial GroupUpgradeHold ➝ Buy$205.00High
1/23/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$173.00 ➝ $180.00Medium
1/17/2018Robert W. BairdReiterated RatingBuy$200.00Low
1/4/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$179.00Low
12/4/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$175.00High
11/9/2017Credit Suisse GroupReiterated RatingUnderperform$155.00 ➝ $130.00N/A
11/1/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$178.00 ➝ $173.00N/A
10/27/2017Royal Bank of CanadaReiterated RatingHold$170.00N/A
10/24/2017MizuhoSet Price TargetHold$168.00N/A
10/24/2017Needham & Company LLCSet Price TargetBuy$179.00 ➝ $178.00N/A
10/18/2017Jefferies Financial GroupSet Price TargetHold$165.00N/A
10/16/2017Needham & Company LLCSet Price TargetBuy$179.00N/A
10/10/2017CowenUpgradeMarket Perform ➝ Outperform$176.00 ➝ $189.00N/A
9/19/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$168.00Low
9/19/2017Robert W. BairdUpgradeNeutral ➝ Outperform$175.00 ➝ $178.00Low
9/14/2017Morgan StanleyDowngradeOverweight ➝ Equal Weight$184.00 ➝ $172.00High
9/8/2017Needham & Company LLCUpgradeHold ➝ Buy$179.00Low
8/29/2017Jefferies Financial GroupSet Price TargetHold$165.00Low
7/27/2017Jefferies Financial GroupUpgradeHold ➝ Buy$153.00Low
6/29/2017SVB LeerinkBoost Price TargetMarket Perform$170.00Medium
6/26/2017UBS GroupReiterated RatingNeutral$156.00 ➝ $166.00N/A
6/4/2017BarclaysSet Price TargetBuy$187.00Low
5/30/2017MizuhoBoost Price TargetNeutral ➝ Neutral$147.00 ➝ $168.00Low
5/25/2017Morgan StanleyBoost Price TargetOverweight$165.00 ➝ $179.00Low
5/23/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$189.00Medium
5/19/2017SVB LeerinkSet Price TargetHold$140.00High
5/19/2017UBS GroupBoost Price TargetNeutral ➝ Neutral$145.00 ➝ $156.00N/A
5/17/2017Jefferies Financial GroupInitiated CoverageHold ➝ Hold$153.00Medium
4/27/2017BarclaysReiterated RatingOverweight$174.00Low
4/21/2017SVB LeerinkReiterated RatingHold$140.00Low
4/17/2017Evercore ISIReiterated RatingOutperform$166.00Low
4/4/2017Needham & Company LLCInitiated CoverageHoldLow
3/6/2017CitigroupBoost Price TargetBuy$169.00 ➝ $175.00N/A
3/3/2017Credit Suisse GroupReiterated RatingSellN/A
1/21/2017SVB LeerinkSet Price TargetHold$155.00N/A
1/18/2017Avondale PartnersUpgradeMarket Perform ➝ Outperform$157.00 ➝ $193.00N/A
1/5/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$171.00 ➝ $169.00N/A
1/3/2017MizuhoDowngradeBuy ➝ Neutral$147.00N/A
11/23/2016Credit Suisse GroupDowngradeNeutral ➝ Underperform$150.00 ➝ $131.00N/A
11/11/2016Standpoint ResearchDowngradeBuy ➝ HoldN/A
11/9/2016MizuhoUpgradeNeutral ➝ Buy$147.00N/A
10/28/2016Standpoint ResearchUpgradeHold ➝ Buy$156.00N/A
10/28/2016Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$196.00 ➝ $153.00N/A
10/28/2016SVB LeerinkDowngradeOutperform ➝ Market PerformN/A
10/28/2016Robert W. BairdDowngradeOutperform ➝ Neutral$200.00 ➝ $164.00N/A
10/5/2016UBS GroupInitiated CoverageNeutral$182.00N/A
9/26/2016MizuhoLower Price TargetNeutral$197.00 ➝ $183.00N/A
9/19/2016ArgusReiterated RatingHoldN/A
9/16/2016The Goldman Sachs GroupDowngradeBuy ➝ Neutral$210.00 ➝ $189.00N/A
9/1/2016SVB LeerinkReiterated RatingOutperform$230.00N/A
8/11/2016MizuhoBoost Price TargetNeutral$174.00 ➝ $197.00N/A
8/9/2016JPMorgan Chase & Co.Boost Price TargetOverweight$210.00 ➝ $221.00N/A
7/28/2016Morgan StanleyBoost Price TargetOverweight$199.00 ➝ $211.00N/A
7/28/2016CitigroupBoost Price TargetBuy$215.00 ➝ $225.00N/A
7/18/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
7/6/2016Avondale PartnersReiterated RatingMarket Perform$172.00 ➝ $197.00N/A
6/30/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
6/30/2016Bank of AmericaReiterated RatingHoldN/A
6/29/2016Robert W. BairdReiterated RatingBuy$220.00N/A
6/29/2016(FBRC)Reiterated RatingBuy$210.00N/A
6/22/2016(FBRC)Reiterated RatingBuyN/A
(Data available from 6/21/2016 forward)
McKesson logo
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Read More

Today's Range

Now: $188.72
Low: $185.32
High: $189.22

50 Day Range

MA: $193.70
Low: $184.89
High: $202.68

52 Week Range

Now: $188.72
Low: $139.76
High: $204.66

Volume

1,145,384 shs

Average Volume

1,069,008 shs

Market Capitalization

$29.85 billion

P/E Ratio

N/A

Dividend Yield

0.91%

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of McKesson?

The following Wall Street analysts have issued stock ratings on McKesson in the last twelve months: Argus, Barclays PLC, Cowen Inc, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Guggenheim, JPMorgan Chase & Co., Mizuho, Morgan Stanley, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for MCK.

What is the current price target for McKesson?

10 Wall Street analysts have set twelve-month price targets for McKesson in the last year. Their average twelve-month price target is $214.00, suggesting a possible upside of 15.7%. The Goldman Sachs Group, Inc. has the highest price target set, predicting MCK will reach $257.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $166.00 for McKesson in the next year.
View the latest price targets for MCK.

What is the current consensus analyst rating for McKesson?

McKesson currently has 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MCK will outperform the market and that investors should add to their positions of McKesson.
View the latest ratings for MCK.

What other companies compete with McKesson?

Other companies that are similar to McKesson include AmerisourceBergen, Cardinal Health, Henry Schein, Patterson Companies and Owens & Minor.

How do I contact McKesson's investor relations team?

McKesson's physical mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The company's listed phone number is 972-446-4800 and its investor relations email address is [email protected] The official website for McKesson is www.mckesson.com.